Do you believe that N-of-1 trials (a clinical trial in which a single patient is the entire trial), are appropriate to evaluate the effectiveness of genomic therapies for rare and/or common genetic disorders? Do gene-editing/targeting therapies have the potential to expedite the advancement of personalized medicine?

Health Science Inquiry encourages authors to publish the work under a Creative Commons Attribution 4.0 International licence (CC BY 4.0) that allows others to distribute, remix, tweak, and build upon the work, even commercially, as long as they credit the Author(s) for the original creation. Authors may however choose to have their work distributed under any of the Creative Commons licenses currently available by specifying their preferred licence in the publication agreement. A description of the Creative Commons licences is available here: